Fundraising Fox
/Companies
Sign in

OpGen

Gaithersburg, US · Delaware corporation · 3 known investors

Find your way into OpGen

197 people in our graph share verified history with the OpGen team — schools, employers, funds. One of them is your warm intro.

Chris Sullivanunlockedknows Vadim Sapiro · together at OpGen (overlapped)
×2knows the team · via The Institute for Genomic Research
×4knows the team · via J. Craig Venter Institute (JCVI)
×5knows the team · via Life Technologies

The page announces the launch of a new fintech arm called CapForce. No further detail about the company's core business is provided on the page.

BiotechFintech

Founders & leadership

EJ
Evan JonesFounder
VS
Vadim SapiroExecutiveVadim Sapiro is an executive officer at OpGen with over 25 years of experience in IT and biotechnology leadership, including work on bioinformatics solutions, clinical IT, and diagnostics. His background spans digital strategy, life sciences commercialization, IT architecture, and regulatory compliance in healthcare and R&D environments.
CE
C. Eric WinzerExecutive
DHDavid Hoekzema
David HoekzemaExecutiveDavid Hoekzema is an executive in life sciences with 35 years of industry experience. He has worked in business development, strategic management, and commercial operations, and has held consulting engagements with biotech firms and in federal R&D contracting.
TW
Terry WalkerExecutive
CD
C. Douglas WhiteExecutive

Board

BG
Brian G. AtwoodBoard director
BS
Bijan SalehizadehBoard director
RW
Ronald W. LennoxBoard director
CM
Corey MulloyBoard directorGeneral Partner at Highland Capital Partners
MU
Misti UshioBoard director
TH
Timothy HoweBoard director

Investors · 3

Digitalis VenturesinferredNew York · $100K – $10M

How we know: board seat on SEC Form D · Not right? Tell us

Highland Capital PartnersreportedCambridge · $1M – $10M

How we know: funding news · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$65M disclosed across 13 of 14 rounds · 2011–2024

▶$3.4MraisedOct 2022 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Johannes BacherExecutive Officer
  • William E. Rhodes IIIDirector
  • Prabhavathi FernandesDirector
  • R. Donald ElseyDirector
  • Mario CrovettoDirector
  • Albert WeberExecutive Officer
  • Oliver SchachtExecutive Officer, Director
Offering amount
$3.4M
Amount sold
$3.4M
Sales commissions
$202.9K
Placement agents
H.C. Wainwright & Co., LLC
First sale
Oct 2022
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$25MraisedFeb 2021 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • William E. Rhodes IIIDirector
  • Mario CrovettoDirector
  • Oliver SchachtExecutive Officer
  • Evan JonesDirector
  • Prabhavathi FernandesDirector
  • Johannes BacherExecutive Officer
  • Timothy C. DecExecutive Officer
  • R. Donald ElseyDirector
Offering amount
$25M
Amount sold
$25M
Sales commissions
$1.5M
Placement agents
Alliance Global Partners
First sale
Feb 2021
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$10MraisedDec 2020 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Johannes BacherExecutive Officer
  • Oliver SchachtExecutive Officer
  • Evan JonesDirector
  • R. Donald ElseyDirector
  • Prabhavathi FernandesDirector
  • William E Rhodes IIIDirector
  • Mario CrovettoDirector
  • Timothy C DecExecutive Officer
Offering amount
$10M
Amount sold
$10M
Sales commissions
$648.3K
Placement agents
Alliance Global Partners
First sale
Nov 2020
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$285.5KraisedAug 2018 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Harry D'AndreaDirector
  • David M RubinDirector
  • Timothy C DecExecutive Officer
  • Timothy J.R. HarrisDirector
  • Tina S NovaDirector
  • Evan JonesExecutive Officer, Director
  • Misti UshioDirector
Offering amount
$285.5K
Amount sold
$285.5K
First sale
Jul 2018
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$110KraisedSep 2017 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Harry D'AndreaDirector
  • Tina S NovaDirector
  • David M RubinDirector
  • Timothy C DecExecutive Officer
  • Timothy J.R. HarrisDirector
  • Evan JonesExecutive Officer, Director
  • Misti UshioDirector
Offering amount
$110K
Amount sold
$110K
First sale
Sep 2017
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$500KraisedJun 2017 · 2 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • David M RubinDirector
  • Misti UshioDirector
  • Tina S NovaDirector
  • Harry D'AndreaDirector
  • Timothy J.R. HarrisDirector
  • Evan JonesExecutive Officer, Director
  • Timothy C DecExecutive Officer
Offering amount
$1.5M
Amount sold
$500K
First sale
Jun 2017
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$7.2MraisedMay 2016 · 10 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Timothy C DecExecutive Officer
  • Timothy HoweDirector
  • Kevin KrenitskyExecutive Officer
  • Timothy J.R. HarrisDirector
  • Evan JonesExecutive Officer, Director
  • Brian G AtwoodDirector
  • David M RubinDirector
  • Misti UshioDirector
  • Laurence R McCarthyDirector
  • Harry D'AndreaDirector
Offering amount
$10.4M
Amount sold
$7.2M
Sales commissions
$694.9K
Placement agents
Leerink Partners LLC, Maxim Group LLC, Cowen and Company
First sale
May 2016
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.6MraisedJul 2015 · 4 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Evan JonesExecutive Officer, Director
  • Kevin KrenitskyExecutive Officer
  • Misti UshioDirector
  • Timothy J.R. HarrisDirector
  • Laurence R McCarthyDirector
  • Vadim SapiroExecutive Officer
  • Timothy HoweDirector
  • Brian G AtwoodDirector
  • David M RubinDirector
  • Timothy C DecExecutive Officer
Offering amount
$2.6M
Amount sold
$2.6M
First sale
Jul 2015
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 10

by search overlap
Amgen Europe27 shared keywordsAmgen develops therapies based on biotechnology and scientific research aimed at treating patients and improving or saving lives. It operates in the biopharmaceutical industry, moving discoveries from the laboratory through clinical development to market.
Biogen Idec21 shared keywordsBiogen is a biotechnology company founded in 1978 that focuses on breakthroughs in biology. The company serves patients through research and development in the life sciences industry.
PepGen19 shared keywordsPepGen is a clinical-stage biotech company developing oligonucleotide therapies for neuromuscular and neurological diseases using its Enhanced Delivery Oligonucleotide (EDO) platform to improve tissue penetration and uptake in muscle tissues.
Public16 shared keywordsPublic is a trading platform that allows users to buy and sell cryptocurrencies including Bitcoin, Ethereum, and memecoins through accounts managed by Zero Hash LLC, a New York State-licensed virtual currency business.
Robinhood16 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Simply Wall St15 shared keywordsSimply Wall St is an investment platform that provides financial data visualization and analysis tools for individual investors. The platform serves long-term investors globally by simplifying complex market information into visual and narrative formats to make stock investing more accessible.
Wugen13 shared keywordsAllotera (formerly Wugen) develops allogeneic T-cell therapies. The company focuses on cell and gene therapy approaches for treating disease.
Urogen13 shared keywordsUroGen is a biotech company developing treatments for urothelial and specialty cancers using a proprietary sustained-release hydrogel platform technology. The company commercializes approved therapies for bladder and upper tract cancers, with additional candidates in development.
StockTwits12 shared keywordsStocktwits operates an online community platform where investors and traders share ideas, analysis, and trade discussions organized around stock tickers. The page presented is its community guidelines rather than a product description.
TradingView12 shared keywordsTradingView is a charting platform and social network used by over 100 million traders and investors worldwide to analyze and trade across global financial markets. The platform provides tools for technical analysis, market data, and community collaboration for retail and institutional traders.

Companies competing with OpGen for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does OpGen do?
The page announces the launch of a new fintech arm called CapForce. No further detail about the company's core business is provided on the page.
Who founded OpGen?
OpGen was founded by Evan Jones.
Who are OpGen's investors?
OpGen's investors include Cross Creek Advisors, Digitalis Ventures, Highland Capital Partners.
How much funding has OpGen raised?
OpGen has disclosed $65M raised across 13 of its 14 known rounds.
Where is OpGen headquartered?
OpGen is headquartered in Gaithersburg, US.